184 related articles for article (PubMed ID: 20490358)
1. The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.
Ecelbarger CM; Rash A; Sinha RK; Tiwari S
Mediators Inflamm; 2010; 2010():841343. PubMed ID: 20490358
[TBL] [Abstract][Full Text] [Related]
2. Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Hu J; Tiwari S; Riazi S; Hu X; Wang X; Ecelbarger CM
Clin Exp Hypertens; 2009 Feb; 31(1):49-63. PubMed ID: 19172459
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Namikoshi T; Tomita N; Satoh M; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
Hypertens Res; 2008 Apr; 31(4):745-55. PubMed ID: 18633187
[TBL] [Abstract][Full Text] [Related]
4. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Sueta D; Nakamura T; Dong YF; Kataoka K; Koibuchi N; Yamamoto E; Toyama K; Yasuda O; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2012 Jun; 25(6):704-10. PubMed ID: 22421905
[TBL] [Abstract][Full Text] [Related]
5. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
[TBL] [Abstract][Full Text] [Related]
6. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats.
Hakam AC; Hussain T
Hypertension; 2005 Feb; 45(2):270-5. PubMed ID: 15596573
[TBL] [Abstract][Full Text] [Related]
7. Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat.
Madala Halagappa VK; Tiwari S; Riazi S; Hu X; Ecelbarger CM
Am J Physiol Renal Physiol; 2008 May; 294(5):F1222-31. PubMed ID: 18305093
[TBL] [Abstract][Full Text] [Related]
8. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Sebeková K; Lill M; Boor P; Heidland A; Amann K
Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
[TBL] [Abstract][Full Text] [Related]
9. Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II.
Wang X; Li F; Jose PA; Ecelbarger CM
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1164-70. PubMed ID: 20810614
[TBL] [Abstract][Full Text] [Related]
10. Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan.
Hadi NR; Yousif NG; Abdulzahra MS; Mohammad BI; Al-Amran FG; Majeed ML; Yousif MG
Cardiovasc Ther; 2013 Dec; 31(6):381-7. PubMed ID: 23566285
[TBL] [Abstract][Full Text] [Related]
11. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
[TBL] [Abstract][Full Text] [Related]
12. Altered pressure-natriuresis in obese Zucker rats.
Fujiwara K; Hayashi K; Matsuda H; Kubota E; Honda M; Ozawa Y; Saruta T
Hypertension; 1999 Jun; 33(6):1470-5. PubMed ID: 10373235
[TBL] [Abstract][Full Text] [Related]
13. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
14. Urinary cytokine profiles according to the site of blockade of the renin-angiotensin system in nephrectomized rats.
Baracho NCDV; Silveira KDD; Rocha NP; Cordeiro TM; Feracin V; Pereira RM; Reis MAAD; Teixeira MM; Silva ACSE
J Bras Nefrol; 2017; 39(2):108-118. PubMed ID: 29069238
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.
Muñoz MC; Giani JF; Dominici FP; Turyn D; Toblli JE
J Hypertens; 2009 Dec; 27(12):2409-20. PubMed ID: 19901849
[TBL] [Abstract][Full Text] [Related]
16. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
17. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
18. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
20. Candesartan ameliorates arsenic-induced hypertensive vascular remodeling by regularizing angiotensin II and TGF-beta signaling in rats.
Khuman MW; Harikumar SK; Sadam A; Kesavan M; Susanth VS; Parida S; Singh KP; Sarkar SN
Toxicology; 2016 Dec; 374():29-41. PubMed ID: 27889505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
